20.-22. September 2019
28. September 2019 Berlin
Location: MIND Foundation @betahaus, Rudi-Dutschke-Straße 23, 10969 Berlin, 1. Floor
Psychedelic-assisted psychotherapy is making waves in psychiatry. A growing body of evidence suggests that one or two doses of LSD and psilocybin, administered in controlled conditions, can reduce symptoms of anxiety, depression, and addiction for many months. A philosophical concern arises from the fact that beneficial outcomes appear to be mediated by drug-induced “mystical-type experiences” of cosmic consciousness. Those sympathetic to a physicalist or naturalist worldview may worry, as Michael Pollan put it, that psychedelic therapy is “simply foisting a comforting delusion on the sick and dying”.
Extant responses to this “Comforting Delusion Objection” include: (i) holding that the cosmic consciousness is real, and so the psychedelic mystical experience is veridical (Richards 2015); (ii) arguing that the epistemic status of the psychedelic experience is less important, in the final analysis, than whether it improves patients’ quality of life (Flanagan and Graham 2017); and (iii) arguing that the epistemic flaws of psychedelic therapy, while real, are counterbalanced by significant epistemic benefits (Letheby 2016). However, none of these responses directly addresses the empirical claim at the heart of the Objection: that the induction of non-naturalistic metaphysical beliefs is the central mechanism whereby psychedelics improve psychosocial functioning.
In this talk I argue against this claim. Qualitative studies of psychedelic therapy suggest that not all patients who satisfy psychometric criteria for a mystical-type experience actually have idealistic experiences as of cosmic consciousness. Some, instead, describe experiences of acceptance, connectedness, embodiment, and “resetting the brain”. Therefore, idealistic experiences and beliefs cannot be the central mechanism of change. However, this does not mean that psychedelic therapy is a pharmacotherapy operating by a non-experiential molecular mechanism. I describe recent theoretical work suggesting that psychedelics induce mystical-type experiences, and bring about therapeutic benefits, by weakening high-level beliefs about self and world that structure ordinary experience. Along the way, I draw out some testable predictions of my account, which provides a case study of productive interaction between philosophy and the mind/brain sciences.
https://www.youtube.com/channel/UCULcga ... -sQ/videos
Mit Vorträgen, u.a. einer praktischen Einführung in die Pilzzucht, am Beispiel von Speisepilzen. Präsentiert von Mitarbeitern des Leibniz-Institut für Naturstoff-Forschung in Jena und weiteren interessanten Vorträgen.
Mit Pflanzenbasar und Saatgutbörse.
Catering: Meister Eckehardts Garküche.
Der Eintritt ist frei.
Conference 16–19 April 2020
Reed Hall, University of Exeter, UK
n recent years a resurgence of studies into psychedelic states of experience has arisen in the cognitive sciences to such an extent as to gain the moniker, The Psychedelic Renaissance. The focus of these scientific studies has been upon the immediate medicinal value that psychedelics may bestow; but the value that the examination of such exceptional experiences may bestow upon the philosophy of mind, phenomenology, ethics, and academic metaphysics is a field yet to be mapped. To such an end, we are pleased to announce a conference on The Philosophy of Psychedelics: Exploring Frameworks for Exceptional Experience – to take place at the University of Exeter in the UK on April 16–19, 2020.
Virtual film premiere featuring short documentary (42 minutes) produced by Horizons with live discussion and Q&A
How did psychedelics, not so long ago cast into the wilderness by the medical community, so quickly return to America’s most prestigious research institutions and graduate to the pages of its premier journals?
Join us as we learn the stories of the scientists who re-opened the doors, and the new generation of researchers working to explore the potential of psychedelics in science and medicine.
https://horizons.nyc/upcoming/focus-on- ... HJVc17KP2g
While much has been made of the potential for psychedelics to improve the lives of those suffering from maladies like depression, addiction, and PTSD, how can they help us face the fears that await all of us at the end of our vital journey?
Join us for the second episode of our Focus on Clinical Research series as we explore how psychedelic experiences can offer insight into the deep questions of mortality, and perhaps offer a pathway to peace for those in existential distress.
https://horizons.nyc/upcoming/death-dyi ... yMKmGI3DvM
BERLIN 9 - 12 SEPTEMBER 2021
The conference presentations are organized into four tracks:
1. Treatment (with the sub–tracks Integration Therapy and Ketamine-assisted therapy)
2. Basic Research
3. Public Health (with the sub–tracks: Anthropology, History, Non-pharmacological methods, Political Regulation and Self Development)
4. Implementation (with the sub-tracks: psychedelic industry, philosophy and ethics of psychedelic states)
You will have the opportunity to watch the conference from the comfort of your home and won‘t miss a single presentation. All ticket buyers can participate via livestream and will have access to the conference’s online platform. Livestream access will be available via PC and smartphone.
In due time before the conference, you will receive more details about how to access the livestream through our newsletter and personal emails.